News archives


OCTOBER - DECEMBER 17

JULY - SEPTEMBER 17

APRIL - JUNE 17

JANUARY - MARCH 17

OCTOBER - DECEMBER 16

JULY - SEPTEMBER 16

APRIL - JUNE 16

JANUARY - MARCH 16

OCTOBER - DECEMBER 15

JULY - SEPTEMBER 15

APRIL - JUNE 15

JANUARY - MARCH 15

OCTOBER - DECEMBER 14

JULY - SEPTEMBER 14

APRIL - JUNE 14

JANUARY - MARCH 14

OCTOBER - DECEMBER 13

JULY - SEPTEMBER 13

APRIL - JUNE 13

JANUARY - MARCH 13

OCTOBER - DECEMBER 12

JULY - SEPTEMBER 12

APRIL - JUNE 12

JANUARY - MARCH 12

OCTOBER - DECEMBER 11

JULY - SEPTEMBER 11

APRIL - JUNE 11

JANUARY - MARCH 11

OCTOBER - DECEMBER 10

JULY - SEPTEMBER 10

APRIL - JUNE 10

JANUARY - MARCH 10

OCTOBER - DECEMBER 09

JULY - SEPTEMBER 09

APRIL - JUNE 09

JANUARY - MARCH 09

OCTOBER - DECEMBER 08

JULY - SEPTEMBER 08

APRIL - JUNE 08

JANUARY - MARCH 08

OCTOBER - DECEMBER 07

JULY - SEPTEMBER 07

APRIL - JUNE 07

JANUARY - MARCH 07

 
  current news   Press   selected story    
     
  25th February 2008  
  Sumana CHANDRAMOULI - IMCBs latest PhD graduate
 
 




Sprouty and Spred as Inhibitors of the RAS-ERK Pathway

Abstract
The Ras-ERK pathway critically regulates several cellular processes including survival, growth and differentiation, and is often deregulated in diseases such as cancer. Two protein families, Sprouty (Spry) and Spred (Sprouty-related protein with EVH1 domain), function as intracellular inhibitors of this pathway downstream of receptor tyrosine kinases (RTKs). Members of both families have been found to be downregulated in various cancers, with their decreased expression correlating with cell transformation, migration and metastasis. Spry and Spred share similarity across a highly-conserved Cys-rich C-terminus, though its role in their ERK inhibitory function remains controversial. In this study, testicular protein kinase 1 (Tesk1) was identified as a common interacting partner to Spry and Spred that binds through this region. Tesk1 coexpression relocalizes Spry2 and Spred1 to vesicles including endosomes, leading to inhibition of their translocation to membrane ruffles upon growth factor stimulation. However, this has different effects on the cellular functions of Spry2 and Spred1. Interaction with Tesk1 abolishes the ERK inhibitory capacity of Spry2 downstream of fibroblast growth factor receptor (FGFR) stimulation while not affecting its regulation of epidermal growth factor receptor (EGFR) ubiquitination. Conversely, Tesk1 binding does not affect ERK inhibition by Spred1. Detailed analysis of the molecular basis for these differences was carried out, and the results highlight the distinct modes of action employed by Spry and Spred in inhibiting RTK signaling.


For more information of Graeme Guy's Lab, Please Click here.